VCEL
Vericel Corporation
NASDAQ · Healthcare · Biotechnology · US
$40.19
−0.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 306.3M | 276.3M | 237.2M | 197.5M | 164.4M |
| Cost of Revenue | 77.9M | 70.7M | 65.1M | 61.9M | 54.6M |
| Gross Profit | 228.4M | 205.6M | 172.1M | 135.6M | 109.8M |
| Operating Expenses | |||||
| R&D Expense | 29.2M | 27.6M | 24.8M | 21.0M | 19.9M |
| SG&A Expense | 181.0M | 167.0M | 142.8M | 121.0M | 106.9M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 210.1M | 194.6M | 167.6M | 142.0M | 126.8M |
| Cost and Expenses | 288.1M | 265.2M | 232.7M | 204.0M | 181.4M |
| Operating Income (EBIT) | 18.2M | 11.0M | 4.5M | (6.5M) | (17.1M) |
| Non-Operating | |||||
| Interest Income | 7.5M | 7.0M | 6.4M | 4.6M | 1.3M |
| Interest Expense | 640.0K | 1.6M | 614.0K | 600.0K | 366.0K |
| Net Interest Income | 6.9M | 5.5M | 5.8M | 4.0M | 975.0K |
| Other Non-Op Income/Expense | 6.8M | 6.3M | 6.0M | 4.1M | 1.1M |
| Non-Operating Income (excl Interest) | (7.5M) | (7.9M) | (6.6M) | (4.7M) | (1.4M) |
| EBT (Pre-Tax Income) | 25.1M | 17.4M | 10.5M | (2.4M) | (16.0M) |
| Income Tax Expense | 859.0K | 859.0K | 148.0K | 814.0K | 721.0K |
| Bottom Line | |||||
| Net Income | 24.2M | 16.5M | 10.4M | (3.2M) | (16.7M) |
| Earnings from Cont. Ops | 24.2M | 16.5M | 10.4M | (3.2M) | (16.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 24.2M | 16.5M | 10.4M | (3.2M) | (16.7M) |
| Per Share | |||||
| Basic EPS | $0.48 | $0.33 | $0.21 | ($0.07) | ($0.35) |
| Diluted EPS | $0.47 | $0.32 | $0.20 | ($0.07) | ($0.35) |
| Revenue Per Share | $6.01 | $5.46 | $4.86 | $4.15 | $3.49 |
| Shares | |||||
| Basic Shares Outstanding | 50.9M | 50.6M | 48.8M | 47.6M | 47.1M |
| Diluted Shares Outstanding | 50.9M | 52.1M | 51.7M | 47.6M | 47.1M |
| Profitability Metrics | |||||
| EBITDA | 38.5M | 30.3M | 16.6M | 2.9M | (11.6M) |
| D&A | 12.7M | 11.4M | 5.5M | 4.6M | 4.0M |
| EBIT | 25.7M | 18.9M | 11.1M | (1.8M) | (15.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026